Clinical Trial

Trial of Perioperative Endocrine Therapy - Individualising Care

Study acronym: POETIC
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 17, 2020 (before its estimated April 2024 completion). Its status may not reflect the trial's current state.
Summary
To determine whether perioperative endocrine therapy with an aromatase inhibitor (AI) followed by standard adjuvant therapy improves outcome compared with standard adjuvant therapy alone in postmenopausal women with hormone receptor positive breast cancer. To determine whether the proliferation marker Ki67 as measured by immunohistochemistry (IHC) in the excised cancer around 2 weeks after starting AI therapy will predict for time to recurrence (TTR) in the individual patient more effectively than the pre-treatment Ki67 value. To determine whether molecular profiling 2 weeks after starting endocrine therapy predicts for long-term outcome in postmenopausal women with hormone receptor positive breast cancer better than at diagnosis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2015-01-09.
Trial Details
NCT Number NCT02338310
Lead Sponsor Institute of Cancer Research, United Kingdom
Conditions Breast Cancer
Enrollment 4,486 participants
Start Date 2008-09
Primary Completion 2024-04 (estimated)
Study Completion 2034-04 (estimated)
Updated on ClinicalTrials.gov 2020-02-17